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1. Introduction  
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and one 
of the most lethal of all human cancers. Despite substantial advances in surgical intervention 
and combining radiotherapy regimens with new generation chemotherapies, the median 
survival for these patients is still about 15 months (Nagane, 2011). In recent years, cancer 
treatments using molecularly targeted drugs that act against the respective molecules have 
been successful, although successful molecular targeted therapies for glioma have yet to be 
established. Because the mechanisms underlying glioma formation and progression are 
complex, many candidate target molecules are identified as potential therapeutic targets 
(Nakada M et al., 2011). To date, the benefit of molecularly targeted therapies is limited, 
although there are many completed and on-going clinical trials (Quant & Wen, 2010). Thus, 
promising molecular targets should be identified to establish innovative molecularly 
targeted therapies against GBM. 
Glycogen synthase kinase 3ǃ (GSK3ǃ) is a serine-threonine protein kinase originally 
identified for its inhibitory role in the conversion of glucose to glycogen via phosphorylation 
and inactivation of glycogen synthase. Recent studies suggest a conflicting role of GSK3ǃ in 
various human cancers, either as a tumor suppressor or tumor promoter. Emerging 
evidence suggests that GSK3ǃ is a tumor promoter in glioma, acting to regulate and link key 
players that control proliferation, resistance to radiochemotherapy, activation of invasion, 
and anti-apoptosis (Kotliarova et al., 2008; Miyashita et al., 2009a; Nowicki et al., 2008). The 
combined anti-proliferative and anti-invasive properties of small molecule GSK3ǃ 
inhibitors make them an attractive treatment modality for controlling GBM. 
The aim of this chapter is to highlight important aspects of the biology of GSK3β, focusing 
on the pathological role, signal transduction, and possibility of being a molecular target for 
GBM.  
2. General knowledge of GSK3β 
GSK3 was discovered in 1980 as a kinase that phosphorylates glycogen synthase, a key 
enzyme involved in glycogen synthesis (Embi et al., 1980). GSK3 is evolutionarily conserved 
and consists of 2 distinct isoforms encoded by 2 different genes, GSK3ǂ and GSK3ǃ, in 
mammals (Woodgett, 1991). GSK3 is ubiquitously expressed, and is highly enriched in the 
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brain. Compared with GSK3ǂ, the GSK3ǃ protein lacks 60 amino acid residues at the N 
terminus, resulting in a lower molecular weight for GSK3ǃ (46.7 kDa). The 2 isoforms share 
extensive homology, most notably in the kinase domain (ATP binding site), which shares 
97% homology. Initially, the primary function attributed to GSK3 was negative regulation of 
glycogen synthesis through phosphorylation and inactivation of glycogen synthase. 
However, further studies have uncovered additional functions of GSK3, such as cell cycle 
regulation, proliferation, differentiation, apoptosis, and migration. Despite high homology, 
the 2 isoforms are not functionally redundant, as demonstrated by gene knockout studies 
(Hoeflich et al., 2000). 
2.1 Biological characteristics of GSK3β 
Although the differences in functional roles of the 2 isoforms are not fully elucidated, 
research thus far has primarily focused on GSK3ǃ. GSK3ǃ is subject to multiple levels of 
regulation mediated by its phosphorylation, subcellular localization, and protein–protein 
interactions. GSK3ǃ protein itself undergoes multiple phosphorylation events, which impact 
its activity depending on the amino acid being modified (Doble & Woodgett, 2003). Tyrosine 
phosphorylation of the GSK3ǃ kinase domain at Tyr216 leads to its activation (Dajani et al., 
2001), whereas phosphorylation of the N-terminal Ser9 results in inhibition of its activity 
and plays an important role in the regulation of GSK3ǃ function (Stambolic & Woodgett, 
1994) (Figure 1).  
 
 
Fig. 1. Phosphorylation and activation of GSK3ǃ. Akt and MAPKAP-K1 phosphorylate Ser9 
of GSK3ǃ, resulting in inhibition of activity. The inhibition of GSK3ǃ decreases the 
phosphorylation of glycogen synthase, leading to an increase in the active form, since 
phosphorylated glycogen synthase is less active. As a result, glycogen synthesis is 
promoted. MAPK: mitogen-activated protein kinase, MAPKAP-K1: MAPK-activated protein 
kinase-1 (also called RSK), Circled P: phosphorylation. 
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One of the main regulators of GSK3ǃ activity is the phosphoinositide 3-kinase (PI3-
kinase)/Akt pathway. PI3-kinase–induced activation of Akt mediates Ser9 phosphorylation 
of GSK3ǃ (Cross et al., 1995; Pap & Cooper, 1998), resulting in the inhibition of GSK3ǃ 
activity. GSK3ǃ can also be phosphorylated at Ser9 by the most downstream kinase of the 
classical mitogen-activated protein kinase (MAPK) cascade, called MAPK-activated protein 
kinase-1 (MAPKAP-K1, also called RSK) (Frame & Cohen, 2001). Apart from this, GSK3ǃ 
functions as a suppressor protein in the Wnt signaling pathway, which is the protein 
network associated with embryo development and cancer progression (Cook et al., 1996; 
Manoukian & Woodgett, 2002; Fuchs et al., 2005). The Wnt pathway was found to have 
essential roles in promoting the survival, proliferation, differentiation, and migration of cells 
in many different tissues, including nervous tissue, as well as in synapse formation in the 
nervous system. Briefly, the Wnt pathway involves the inhibition of an inhibitor, leading to 
activation of a transcription factor. When Wnt signal is absent, GSK3ǃ associates with other 
proteins (e.g., axin, adenomatous polyposis coli [APC]) and functions as a critical mediator 
of the pathway. In this situation, the proto-oncoprotein ǃ-catenin is constitutively 
phosphorylated, rapidly removed by degradation, and thus, will not build up in the cell to a 
significant level (Hagen & Vidal-Puig, 2002). In contrast, when Wnt binds to frizzled (Frz), 
its receptor, dishevelled (Dsh) is recruited to the cell membrane. GSK3ǃ is inhibited by the 
activation of Dsh. Consequently, ǃ-catenin, having escaped ubiquitination-dependent 
proteasomal degradation mediated by GSK3ǃ phosphorylation, accumulates in the 
cytoplasm. It is subsequently shifted to the nucleus, where it assembles with other proteins 
(e.g., T-cell factor [Tcf]/lymphoid enhancer factor [Lef]) to switch on transcription of specific 
target genes, leading to its function as an oncoprotein. In this mechanism, GSK3ǃ is thought 
of as a tumor suppressor protein (Figure 2). 
GSK3ǃ acts as a downstream regulatory switch that determines the output of numerous 
signaling pathways initiated by diverse stimuli (Frame & Cohen, 2001). Phosphorylation of 
GSK3ǃ (Ser9) leads to the dephosphorylation of substrates, including glycogen synthase and 
translation factor eukaryotic protein synthesis initiation factor-2B (eIF-2B) (Welsh et al., 
1998), resulting in their functional activation and consequent increase in glycogen synthesis, 
release of a number of transcription factors from tonic inhibition, and protein synthesis 
(Cohen & Frame, 2001). Thus, GSK3ǃ affects both key components of the response to 
stimuli, reprogramming of gene expression, and activation of protein synthesis. 
Additionally, GSK3ǃ phosphorylates a broad range of substrates: c-myc (Gregory et al., 
2003), c-Jun (Boyle et al., 1991), c-Myb (Kitagawa et al., 2010), cyclin D1 (Diehl et al., 1998), 
Cdc25A (Kang et al., 2008), nuclear factor of activated T-cells (Beals et al., 1997), heat shock 
factor-1 (He et al., 1998; Xavier et al., 2000), Mcl-1 (Ding et al., 2007), cAMP response 
element-binding protein (Bullock & Habener, 1998), and so on. GSK3ǃ can target these 
substrates for degradation or inactivation, resulting in inhibition of cell proliferation and 
self-renewal. GSK3ǃ also regulates nuclear factor (NF)-κB stability and activity (Demarchi et 
al., 2003; Hoeflich et al., 2000). These findings identified GSK3ǃ as a key determinant in both 
physiological and pathological conditions, such as glycogen metabolism, insulin signaling, 
cell fate, neuronal function, and oncogenesis. 
2.2 Physiological function 
GSK3ǃ participates in a number of different cellular pathways in a context-dependent 
manner and is implicated in the regulation of a wide range of cellular processes, including 
apoptosis, cell proliferation, and migration. Multiple lines of evidence indicate that the 
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function of GSK3ǃ is opposing in different cell types. This functional dichotomy suggests 
that the function of GSK3ǃ seems to be dependent on cell-types and/or cell conditions, 
which are physiological and pathological. 
 
 
 
Fig. 2. Role of GSK3ǃ in the Wnt pathway. When Wnt signal is absent, GSK3ǃ promotes the 
proteasomal degradation of ǃ-catenin. In contrast, when Wnt binds to frizzled (Frz), its 
receptor, dishevelled (Dsh) is recruited to the cell membrane. GSK3ǃ is inhibited by the 
activation of Dsh. Consequently, ǃ-catenin accumulates in the cytoplasm and is 
subsequently translocated into the nucleus to switch on Tcf/Lef-dependent transcription of 
specific target genes, leading it to act as an oncoprotein. Note that there are other regulatory 
components of each pathway; this schema was simplified for clarity. 
2.2.1 Apoptosis 
GSK3ǃ is a component of signaling cascades involved in the process of apoptosis  (Iqbal & 
Grundke-Iqbal, 2008) and is a critical downstream element of the PI3-kinase/Akt cell survival 
pathway (Pap & Cooper, 1998). Transient overexpression of GSK3ǃ was found to induce 
spontaneous apoptosis in PC12 cells, used as a model system for neuronal differentiation, in a 
caspase-3-dependent manner (Pap & Cooper, 1998). Inhibition of GSK3ǃ activity prevented 
cell death by blocking mitochondrial membrane potential changes and subsequent caspase-9 
and caspase-3 activation in murine TSM1 neuronal cells (Petit-Paitel et al., 2009).  
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2.2.2 Proliferation 
GSK3ǃ is involved in cell proliferation through the canonical Wnt/ǃ-catenin signaling 
pathway. GSK3ǃ inhibition promotes translocation of dephosphorylated and stabilized ǃ-
catenin to the nucleus and its interaction with transcription factors, resulting in the 
induction of genes responsible for cell proliferation. Lithium chloride (LiCl), a chemical 
GSK3ǃ inhibitor, significantly increased the proliferative potency of thyrocytes that 
appeared to be mediated by ǃ-catenin (Rao et al., 2005). Similarly, the small molecule 6-
bromoindirubin-3′-oxime (BIO), a specific inhibitor for GSK3, promotes proliferation in 
mammalian cardiomyocytes by elevated ǃ-catenin activity (Tseng et al., 2006). In addition, it 
is known that inhibition of GSK3ǃ promotes vascular cell proliferation, suggesting that 
active GSK3ǃ inhibits angiogenesis (Hou et al., 2010). GSK3ǃ signaling also plays an 
essential role in regulating the differentiation and proliferation of adult neural stem cells. 
Inhibition of GSK3ǃ results in transcriptional activation of distinct target genes via ǃ-
catenin, leading to an increase in the number of neurons that differentiated from 
neurospheres (Maurer et al., 2007).  
2.2.3 Migration 
It has also been shown that, during cell migration, GSK3ǃ plays a positive role in activating 
Rac, a Rho family member, and ADP-ribosylation factor 6 (Arf6), a related small GTPase, in 
adherent cells. Rac is responsible for forming lamellipodia during cell migration. Arf6 is also 
involved in vesicle trafficking, membrane ruffling, as well as lamellipodia formation (Turner 
& Brown, 2001). It has been shown that GSK3ǃ activity is required for keratinocytes to form 
lamellipodia and migrate directionally in response to wound signaling (Koivisto et al., 
2003). Similarly, GSK3ǃ activates Rac in response to wound signaling in intestinal epithelial 
cells. When GSK3ǃ is inhibited, and thus Rac activation prevented, these cells stop moving 
(Vaidya et al., 2006). Although the mechanisms by which guanine nucleotide exchange 
factor (GEF) and GTPase-activating protein (GAP) regulate Rac or Arf6 have been 
extensively studied, no direct evidence has demonstrated that GSK3ǃ modifies these GEFs 
and GAPs. 
Focal adhesion kinase (FAK) is another candidate that contributes to the regulation of cell 
migration by GSK3ǃ. FAK tyrosine phosphorylation and Rac activation were suppressed in 
GSK3ǃ knocked-down HeLa S3 (human cervical carcinoma cell line) cells, suggesting that 
GSK3ǃ mediates the disassembly of focal adhesions to promote cell migration (Kobayashi et 
al., 2006). In contrast, Bianchi et al. showed that GSK3ǃ reduces FAK kinase activity and cell 
motility in rat fibroblasts and HEK-293 (human embryonic kidney 293) cells. The influence 
of GSK3ǃ on migration of various types of cells (e.g., neoplastic and non-neoplastic) appears 
to be complex. Further identification of additional GSK3ǃ targets and more detailed studies 
of the pathways affecting cell migration will be necessary to clarify the function of GSK3ǃ in 
cell migration (Sun et al., 2009). 
2.3 Pathological function 
GSK3ǃ is ubiquitously expressed at high levels in the brain. Numerous studies have 
indicated that GSK3ǃ is involved in key functions of the brain and is associated with a 
variety of neurological disorders like Alzheimer, Parkinson, and Huntington diseases, as 
well as affective disorders and other neurodegenerative disorders (Grimes & Jope, 2001; 
Jope & Roh, 2006). Additionally, it is not surprising that GSK3ǃ has been implicated in 
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glucose intolerance, considering its primary role is as a negative regulator of insulin-
mediated glycogen synthesis and glucose homeostasis. Indeed, the activity of GSK3ǃ has 
been reported in type II diabetes mellitus and obese animal models (Eldar-Finkelman et al., 
1999; Nikoulina et al., 2000). GSK3ǃ is also involved in inflammation that accompanies 
various kinds of diseases (reviewed in Jope et al., 2007). GSK3ǃ inhibition attenuates 
activation of the pro-inflammatory transcription factor NF-κB and activates the 
immunomodulatory transcription factor ǃ-catenin (Gong et al., 2008). GSK3ǃ inhibition also 
induces secretion of the anti-inflammatory cytokine IL-10 (Hu et al., 2006).  
More recent studies indicate a role for GSK3ǃ in the control of neoplastic transformation and 
tumor development (reviewd in Miyashita et al., 2009b). Overexpression and activation of 
GSK3ǃ was confirmed in various kinds of cancers such as colorectal, stomach, pancreatic, 
and liver cancers, as well as leukemia and GBM (Shakoori et al., 2005; Shakoori et al., 2007; 
Wang et al., 2008; Miyashita et al., 2009a; Mai et al., 2009). Previous studies have shown that 
inhibition of GSK3ǃ suppresses cancer cell proliferation and induces apoptosis (Ougolkov et 
al., 2005; Ougolkov et al., 2007). In these cancers, the function of GSK3ǃ is critical for 
malignant phenotype with respect to proliferation and invasion. Accumulated evidence 
supports the role of GSK3ǃ in the regulation of apoptosis and proliferation appears to be 
diverse between physiological and pathological conditions. 
However, the exact role of GSK3ǃ in malignancies remains highly controversial due to the 
conflicting results from different tumor models. It has been shown that GSK3ǃ is a tumor 
suppressor protein that controls cellular fate determination and stem cell maintenance 
through inhibition of the Wnt, Hedgehog, and Notch pathways. These pathways are 
aberrantly activated in several cancers (Saldanha, 2001; Waaler et al., 2011). This suggests 
that GSK3ǃ inhibitors could exert a therapeutically negative, pro-survival effect on tumor 
cells. In addition, some studies found that GSK3ǃ is part of a tumor suppressor complex 
consisting of axin and APC that phosphorylates the oncoprotein ǃ-catenin and that, when 
GSK3ǃ is inactivated, could possibly lead to tumor promotion (Hinoi et al., 2000; Rask et al., 
2003). Available evidence indicates that GSK3ǃ may function as a “tumor suppressor” for 
certain types of tumors such as skin and mammary tumors (Farago et al., 2005; Ma et al., 
2007). These findings suggest that the mechanisms underlying the function of GSK3ǃ as a 
tumor promoter or suppressor might depend on cell type and tissue context.  
3. GSK3β biology in glioma 
Recently, 3 independent research groups, including our group, simultaneously reported that 
GSK3ǃ is a key promoter of malignant GBM phenotypes and is thus a promising candidate 
for molecular-targeted therapy (Kotliarova et al., 2008; Nowicki et al., 2008; Miyashita et al., 
2009a).  
3.1 Expression and activation 
GSK3ǃ is consistently expressed in primary GBM (Korur et al., 2009; Li et al., 2010). High 
expression levels of GSK3ǃ and phosphorylated GSK3ǃ (Tyr216) were detected in GBM 
compared with non-neoplastic brain tissues (Miyashita et al., 2009a). This finding identified 
GSK3ǃ as an important regulator of malignant phenotype in GBM cells. GSK3ǃ is 
constitutively active in GBM cells, despite the fact that PI3K/Akt, which can inhibit GSK3ǃ 
activity, is a major signaling pathway in GBM. It is possible that an undetermined pathway 
www.intechopen.com
 
The Pivotal Roles of GSK3β in Glioma Biology 
 
573 
other than that mediated by Akt prevents GSK3ǃ Ser9 phosphorylation (Shakoori et al., 
2005), allowing GSK3ǃ to be constitutively active in GBM cells.  
3.2 Localization in tumor cells 
Overexpression of GSK3ǃ was observed in the cytoplasm of neoplastic cells in GBM, 
whereas only weak expression was observed in the cytoplasm of neurons from non-
neoplastic tissue (Miyashita et al., 2009a).  
3.3 Function 
GSK3ǃ function in glioma has been investigated by inhibiting GSK3ǃ using small interfering 
RNA (siRNA), the small-molecule inhibitors LiCl or thiazolidinediones (TZD), and a small 
heterocyclic compound first described as a non-ATP competitive inhibitor of GSK3ǃ. 
Inhibition of GSK3ǃ activity attenuated proliferation, inhibited cell survival, enhanced 
tumor cell apoptosis, induced tumor cell differentiation, impaired formation of 
neurospheres, and reduced clonogenicity of GBM cells in a dose-dependent manner 
(Aguilar-Morante et al., 2010; Korur et al., 2009; Kotliarova et al., 2008; Miyashita et al., 
2009a) (Table 1). The cytotoxic effects are directly correlated with decreased enzyme-
activating phosphorylation of GSK3ǃ (Tyr216) (Kotliarova et al., 2008). Furthermore, specific 
pharmacologic GSK3ǃ inhibitors and siRNA knockdown of GSK3ǃ reduced glioma cell 
motility (Nowicki et al., 2008). Importantly, administration of a highly specific GSK3ǃ 
inhibitor, AR-A014418 (Bhat et al., 2003), at a low dose sensitized GBM cells to 
chemotherapeutic agents such as temozolomide and ionizing radiation, resulting in reduced 
cell viability (Miyashita et al., 2009a).  
 
 
 
Table 1. Disadvantageous effects of GSK3ǃ inhibition for glioma 
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4. GSK3β-mediated signaling in glioma 
4.1 Apoptosis 
The molecules associated with GSK3ǃ were also assessed by GSK3ǃ inhibition. Several 
signaling pathways are associated with the decreased cell survival related to GSK3ǃ 
inhibition. Inhibition of GSK3ǃ activates the oncogenic transcription factor c-myc, leading to 
the induction of apoptosis promoting factors such as Bax, Bim, DR4/DR5, and tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), as well as subsequent 
cytotoxicity (Kotliarova et al., 2008). In addition, inhibition of GSK3ǃ was associated with 
increased expression of p53 and p21 in GBM cells with wild-type p53. Simultaneously, the 
phosphorylated fraction of retinoblastoma protein (Rb) (inactive form) decreased, which 
associated with down-regulation of cyclin-dependent kinase 6 (CDK6) (Miyashita et al., 
2009a). It has been reported that decreased phosphorylation of Rb (activation of Rb) could 
be attributed to the down-regulation of CDK6 (Classon & Harlow, 2002). These signaling 
pathways probably induce apoptosis by inhibition of GSK3ǃ in GBM cells. In contrast to the 
GSK3ǃ phosphorylates the Thr366 residue of PTEN that negatively regulates PI3K and then 
reduces Akt activity. Blocking phosphorylation of PTEN by either mutating or inhibiting 
GSK3ǃ in GBM cell lines leads to stabilization of the PTEN protein (Maccario et al., 2007). In 
this situation, PTEN can work stably as a suppressor for PI3K/Akt, leading to apoptosis 
(Figure 3).  
4.2 Proliferation 
One of the major targets of GSK3ǃ is NF-κB, which is an intracellular protein complex that 
controls DNA transcription and is a pro-survival factor in glioma (Kasuga et al., 2004; Robe 
et al., 2004). Inhibition of GSK3ǃ activity by GSK3ǃ-specific inhibitors such as LiCl and by 
GSK3ǃ siRNA caused a dramatic decrease in intracellular NF-κB activity in U251, T98, and 
U87 GBM cell lines (Kotliarova et al., 2008). NF-κB inhibition then resulted in decreased 
glioma cell survival in vitro and inhibition of tumor growth in vivo (Kotliarova et al., 2008) 
(Figure 3). TZD-8 can inhibit GSK3ǃ activity not only by directly interacting with this 
enzyme, but also by phosphorylating the Ser9 residue of GSK3ǃ via MAPK pathway 
activation. TZD-8 suppresses the growth of glioma cells in vivo and exerts anti-proliferative 
and pro-apoptotic activities in glioma cells in vitro (Aguilar-Morante et al., 2010). These 
effects were accompanied by an activation of the MAPK signaling pathway, concomitant 
phosphorylation of Ser9, inactivation of GSK3ǃ, and an inhibition of NF-κB activity. These 
results are consistent with previously published data, showing that an activation of MAPK 
is associated with a reduction in cell survival in different tumor cell lines, including GBM 
cell lines (Tewari et al., 2008). In contrast, GSK3ǃ inhibition promotes entrance of ǃ-catenin 
to the nucleus and the interaction of ǃ-catenin with transcription factors. While this could 
promote cell proliferation, it does not take place, presumably, because of the simultaneous 
action of other pathways, which inhibit glioma cell proliferation (Kotliarova, 2008). 
4.3 Migration/invasion 
Specific inhibitors and siRNA knockdown of GSK3ǃ both reduced glioma cell motility. The 
effects are dose dependent and reversible (Nowicki et al., 2008). However, the mechanisms 
underlying the effect of GSK3ǃ on glioma cell migration and invasion required further 
study. Migration of GBM cells requires the formation of lamellipodia at the cell front and 
stress fibers consisting of actomyosin at the rear; contraction of these stress fibers causes the 
cell to reacquire front-rear symmetry. The migrating morphology of GBM cells is dependent  
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Fig. 3. GSK3ǃ-mediated signaling in glioma. The signaling pathways associated with 
apoptosis, proliferation, angiogenesis, cell stemness, and glycogen synthesis are depicted. 
Apoptosis: GSK3ǃ activity results in c-myc inhibition that consequently decreases 
expression of Bax, Bim, DR4/DR5, and TRAIL, preventing subsequent cytotoxicity. GSK3ǃ 
increases the levels of Rb phosphorylation, resulting in Rb inactivation. Decreased Rb 
phosphorylation is associated with down-regulation of CDK6. GSK3ǃ destabilizes PTEN, 
which negatively regulates PI3K and reduces Akt activity. Proliferation: siRNA targeting 
GSK3ǃ causes a dramatic decrease in intracellular NF-κB activity. NF-κB inhibition results in 
decreased glioma cell survival. Angiogenesis: Hypoxia activates RhoB. HIF-1ǂ may be 
regulated by RhoB through the Akt/GSK3ǃ pathway under hypoxic conditions, although 
there is no data proving direct inhibition of HIF-1ǂ by GSK3ǃ. Stemness: Expression of 
GSK3ǃ is reduced by down-regulation of polycomb group protein Bmi1. Inhibition of Bmi1 
induces a differentiation phenotype and reduces expression of Nestin and Sox2 in glioma 
cells. Glycogen synthesis: GSK3ǃ stabilizes HKII on the outer mitochondrial membrane, 
thereby supporting glycolysis. Bax: BCL2-associated X protein, Bim: BCL2 interacting 
protein, DR4/DR5: death receptor 4/death receptor 5, HIF-1ǂ: hypoxia-inducible factor 1ǂ, 
HKII: hexokinase-II, NF-κB: nuclear factor-kappa B, PI3K: phosphatidylinositol 3-kinases, 
PTEN: phosphatase and tensin homolog, Rb: retinoblastoma protein, RhoB: Ras homolog 
gene family member B, Sox2: SRY (sex determining region Y)-box 2, TRAIL: tumor necrosis 
factor (TNF)-related apoptosis-inducing ligand, Circled P, phosphorylation. 
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on the balance between Rac1, whose activity is largely responsible for lamellipodia 
formation, and RhoA, which is related to stress fiber formation. Interference with 
lamellipodia by the inhibition of Rac1 reduces migration. This also causes GBM cells to 
acquire a relatively round shape without extending cell processes (Chuang et al., 2004). In 
contrast, collapse of actin stress fiber formation by the inhibition of RhoA promotes 
migration (Salhia et al., 2005). As LiCl treatment is associated with a marked change in GBM 
cell morphology, with cells retracting their long extensions at their leading edge and losing 
lamellipodia formation (Nowicki et al., 2008), GSK3ǃ signaling may involve small GTPases 
such as Rac1 and RhoA. 
4.4 Angiogenesis (signal induced by hypoxia) 
A hypoxic microenvironment is a striking characteristic of GBM that is the collective 
consequence of morphologically and functionally immature neovascularization, irregular 
blood flow, anemia, and high oxygen consumption due to rapidly proliferating malignant 
cells (Jensen, 2009). The hypoxic microenvironment is a powerful stimulus for the 
expression of genes involved in tumor cell proliferation and angiogenesis (Carmeliet et al., 
1998). Hypoxia markedly increases the inactive GSK3ǃ fraction and decreases the active 
GSK3ǃ fraction in U87 GBM cells. In U87 cells under hypoxia, depletion of Ras homolog 
gene family member B (RhoB) by siRNA decreases the inactive form of GSK3ǃ and increases 
active GSK3ǃ. At the same time, RhoB inhibition induces degradation of hypoxia-inducible 
factor 1ǂ (HIF-1ǂ) in the proteasome (Skuli et al., 2006). These experimental data suggest 
that GSK3ǃ controls RhoB-dependent HIF-1ǂ stabilization under hypoxic conditions (Figure 
3). The transcription factor, HIF-1, is an essential regulator of oxygen homeostasis by 
controlling a battery of target genes involved in angiogenesis, glycolysis, proliferation, and 
pH regulation (Semenza, 2009). According to this mechanism, it was shown that inhibition 
of RhoB in GBM xenografts leads to a decrease in vessel density (Ader et al., 2003). 
Considering the role of RhoB in the stimulation of angiogenesis, as well as the presumed 
connection between RhoB expression and GSK3ǃ activity, it is reasonable to speculate that 
GSK3ǃ activity in hypoxic conditions can regulate angiogenesis in GBM. However, the 
precise effect of GSK3ǃ inhibition on angiogenesis has yet to be identified. 
4.5 Cell stemness 
GSK3ǃ activity appears to regulate glioma stem cell populations. GSK3ǃ protein, as well as 
stem cell markers Nestin and Notch2, are highly expressed in CD133+ populations, which 
was identified as a surface marker of cancer stem cells in brain tumors (Singh et al., 2004). 
Down-regulating GSK3ǃ specifically decreased the subpopulation of cancer cells, with a 50–
60% depletion of CD133+ cells that possessed a cancer stem cell-like signature. This 
depletion was attributed to the differentiation of the cell subtype. Additionally, reduction of 
Nestin in GBM stem cell cultures treated with GSK3ǃ inhibitor at the molecular level 
indicated loss of cell stemness (Aguilar-Morante, 2010). Indeed, inhibition of GSK3ǃ reduces 
the GBM stem cell pool and induces phenotypic switch towards differentiation in GBM cell 
cultures. This increases the expression of differentiation markers such as neuronal marker ǃ-
tubulin III, oligodendrocyte-specific marker CNPase, and astrocytic marker GFAP (Korur et 
al., 2009). One explanation for this mechanism is as follows. shRNA-mediated depletion of 
Bmi1, a polycomb group protein that is required for neural stem cell self-renewal, reduced 
expression of GSK3ǃ in glioma. This decreased expression of Sox2 and Nestin in glioma cells 
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and induced cell differentiation, suggesting a putative functional link between GSK3ǃ and 
Bmi1 in glioma cell stemness (Figure 3). 
Neurosphere formation is a representative feature of glioma stem cells. GSK3ǃ inhibition 
significantly reduced the number and volume of neurospheres in glioma cells (Korur et al., 
2009). Primary neurosphere cultures treated with TZD-8 failed to give rise to secondary 
neurospheres, indicating that self-renewing stem cells are lost under TZD-8 treatment 
(Aguilar-Morante et al., 2010). TZD-8 inhibits the proliferation and expansion of these 
neurospheres and hampered their capacity for self-renewal, suggesting that TZD-8 could 
reduce the tumor-initiating cells (Aguilar-Morante et al., 2010). Furthermore, reduction in 
the levels of Nestin protein in GBM stem cell cultures treated with TZD-8 indicated a loss of 
cell stemness induced by GSK3ǃ inhibition (Aguilar-Morante et al., 2010). Taken together, 
GSK3ǃ activation is identified as a key element in maintaining stem cell-like characteristics 
in a subset of glioma cells, providing these cells with a higher self-renewal capacity. 
In contrast, there is a recent contradictory report showing that forced expression of GSK3ǃ 
induces cellular differentiation of malignant glioma cells to normal astrocytes. Conversely, 
GSK3ǃ suppression inhibits differentiation and is accompanied by the interruption of cyclin 
D1 proteolysis, which is necessary for the astrocytic differentiation of malignant glioma cells 
(Li et al., 2010). The exact mechanisms underlying the effect of GSK3ǃ on glioma cell 
differentiation require more detailed study. 
4.6 Metabolism 
Increased glycolysis is characteristic of malignancy. Glioma cell growth is closely associated 
with glucose metabolism. Down-regulation of GSK3ǃ activity results in changes of 
intracellular glucose metabolism (Kotliarova et al., 2008). The activity of mitochondrial 
hexokinase, an enzyme that localizes at the outer mitochondrial membrane and metabolizes 
glucose in rapidly-growing glioma cells, is about 3 times higher than that in slow-growing 
cells. Consistently, the intracellular glucose concentration is undetectable in rapidly-
growing glioma cells, suggesting that glucose catabolism is activated in these cells 
(Nagamatsu et al., 1996). The dissociation of hexokinase from the outer mitochondrial 
membrane by GSK3ǃ inhibition is partially responsible for the reduction in intracellular 
glucose concentration (Kotliarova et al., 2008). However, the reduction of intracellular 
glucose after GSK3ǃ inhibition is mainly due to decreased GSK3ǃ-dependent glycogen 
synthase phosphorylation. This leads to glycogen synthase activation and consequently to 
the increased intracellular glycogen (Figure 1). Further studies are necessary to examine 
whether the forced glucose consumption and subsequent accumulation of glycogen by 
GSK3ǃ inhibition affects the glioma phenotype. However, it may be possible that GBM cells 
cannot use glucose effectively for cell proliferation and survival due to the lack of glucose 
under the condition induced by GSK3ǃ inhibition. 
4.7 Chemosensitivity 
One of the potential molecules involved in the chemosensitization associated with GSK3ǃ 
inhibition in GBM cells is O6-methylguanine-DNA methyltransferase (MGMT), a DNA 
repair enzyme and major determinant of temozolomide cytotoxicity. Recently, clinical 
research has revealed that the methylation status of the MGMT promoter is associated with 
the prognostic outcome of GBM patients treated with temozolomide (Hegi et al., 2005). 
Reduction of MGMT expression induced by p53 in GBM cells renders them sensitive to 
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temozolomide (Natsume et al., 2005). It is reasonable to speculate that increased expression 
of p53 by GSK3ǃ inhibition enhances temozolomide chemosensitivity through the reduction 
of MGMT (Miyashita et al, 2009a).  
4.8 Neuroprotection 
Radiation is a standard post-operative therapy for patients with GBM. Intellectual 
impairment, reduction in performance IQ, memory loss, and dementia have been reported 
after exposure of the brain to radiation. However, the exact mechanisms of radiation-
induced brain injury remain unknown and prevention of cranial radiation-induced 
morbidity remains challenging. Recent studies indicate that inhibition of GSK3ǃ protects 
hippocampal neurons from radiation–induced apoptosis and attenuation of neurocognitive 
dysfunction resulting from cranial radiation (Thotala et al., 2008; Yang et al., 2011). 
Inhibition of GSK3ǃ accelerated double strand-break repair efficiency in irradiated mouse 
hippocampal neurons, whereas, none of these effects were observed in GBM cells, 
suggesting potential clinical application of neuroprotection with GSK3ǃ inhibitors during 
cranial radiation. 
5. GSK3β as a therapeutic target 
In the field of medicinal chemistry, GSK3ǃ has recently emerged as one of the most 
attractive therapeutic targets for the development of selective inhibitors as promising new 
drugs for diabetes. Several potent GSK3 inhibitors have been developed by pharmaceutical 
companies in preclinical models for diabetes treatment. Apart from this, inhibitors of GSK3ǃ 
have enormous potential as therapeutics for a number of serious pathologies, including 
Alzheimer's disease, bipolar disorders, chronic inflammatory processes, and cancer. GSK3ǃ 
inhibitors are being actively developed as drugs for the treatment of these various disorders. 
The therapeutic effect of GSK3ǃ inhibition has been confirmed to inhibit inflammation in 
several studies (Jope et al., 2007). Concerns for the therapeutic use of GSK3ǃ inhibitors 
remain because they may activate oncogenic (e.g., Wnt) signaling, thus promoting cell 
proliferation. Certainly, however, this concern has not deterred preclinical studies of GSK3ǃ 
inhibitors in the treatment of many types of cancers, as discussed above, or Phase II clinical 
trials for the treatment of neurological diseases (Chico et al., 2009).  
5.1 GSK3β-targeted therapy for cancers in clinic  
The need for accurate determination of GSK3β status is illustrated by the excellent results of 
therapies targeting GSK3β in clinic. These strategies have been shown to benefit only tumors 
overexpressing the GSK3β protein. In other words, tumors that do not express GSK3β do 
not benefit from GSK3β-targeted therapies. To date, there are no clinical trial reports 
describing the use of specific GSK3β inhibitors for cancers, although many basic research 
results identified GSK3β as a tumor promoter and suitable candidate for targeted treatment. 
Chemical drugs already prescribed for other diseases were shown to have an inhibitory 
effect on GSK3β.  
5.1.1 Lithium chloride (LiCl) 
LiCl is highly effective in the treatment of bipolar disorder (Bowden et al., 2005). Results 
from an epidemiological study indicated that cancer prevalence in psychiatric patients on 
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long-term LiCl medication was lower than in the general population (Cohen et al., 1998), 
suggesting that administration of LiCl induces cell differentiation and inhibits proliferation 
and, therefore, might effectively inhibit tumor formation and progression. GSK3β has 
emerged as a key target that is central to the effects of LiCl treatment. There are 2 
mechanisms by which LiCl inhibits GSK3β (Figure 4). Firstly, LiCl promotes Ser9 
phosphorylation in GSK3β, resulting in a less active form of GSK3β (Jope, 2003). Secondly, 
LiCl blocks the function of activated GSK3β by competing with magnesium ions (Mg2+) 
(Jope, 2003). Mg2+ is required for activated GSK3β to phosphorylate its substrates, which are 
involved in the propagation of chemical signals required for cell survival, proliferation, and 
differentiation. As a consequence of these inhibitory effects, GSK3β can no longer regulate 
many important biological processes. It is notable that LiCl protects hippocampal neurons 
from radiation–induced apoptosis by promoting the DNA repair pathway, probably a result 
of the effect of GSK3β inhibition (Yang et al., 2009; Yang et al., 2011). 
 
 
Fig. 4. Therapeutic mechanism of GSK3β inhibition in clinic. Lithium chloride (LiCl) inhibits 
phosphorylation of GSK3β substrates by competing with Mg2+, which is required for 
GSK3β-dependent substrate phosphorylation. Simultaneously, LiCl and olanzapine increase 
the phosphorylation of the Ser9 residue. Valproic acid (VPA) inhibits GSK3β by direct 
interaction. LiCl and VPA show additive effects on GSK3β inhibition. Like a 
pharmacological GSK3β inhibitor AR-A014418, olanzapine can be successfully docked 
within the adenosine triphosphate (ATP)-binding pocket of GSK3β. Cimetidine, 
gemifloxacin, and hydroxychloroquine are potent GSK3β inhibitors with at least 2 distinct 
binding modes accessible to ligands within the GSK3β binding pocket. Circled P, 
phosphorylation. 
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5.1.2 Valproic acid (VPA)  
VPA is now an established drug for the treatment of epileptic seizures (absence, tonic-clonic, 
and complex partial seizures) and mania in bipolar disorder (Kostrouchova & Kostrouch, 
2007). VPA affects multiple cell regulatory pathways. The best substantiated molecular 
mechanism of VPA action is its inhibitory effect on histone deacetylase (HDAC) activity, a 
key regulator in the dynamics of chromatin structure and function. It was proposed that 
VPA activates Wnt-dependent gene expression through inhibition of HDAC, which 
generated interest for its use in cancer therapy (Phiel et al., 2001). Apart from this, VPA, like 
LiCl, exerts significant inhibitory effects on the activity of GSK3β both directly in vitro and 
also on endogenous GSK3β in intact human neuroblastoma SY5Y cells (Chen et al., 1999) 
(Figure 4). The dual inhibition of HDAC and GSK3β by VPA may provide a basis for its 
anticancer activity. As expected, clinical trials using VPA for cancer showed some effects 
(Chateauvieux et al., 2010). 
Significant inhibitory effects for GSK3β are clearly observed at VPA concentrations 
approximating those attained clinically during treatment. Furthermore, addition of LiCl at 
therapeutic concentrations results in additive inhibitory effects to that of VPA. These 
additive effects of LiCl and VPA on GSK3β suggest that the 2 drugs may exert their effects at 
different sites, but additional studies will be necessary to establish this definitively (Chen et 
al., 1999). 
5.1.3 Olanzapine 
Olanzapine is broadly used for patients with schizophrenia. Recently, olanzapine was 
identified as a GSK3β inhibitor by a docking simulation experiment, which validates the 
interaction between the drug and its target molecule. Olanzapine, as well as the well-known 
GSK3β inhibitor AR-A014418, were found to readily fit within the adenosine triphosphate 
(ATP)-binding pocket of GSK3β and to inhibit its activity (Mohammad et al., 2008). 
Additionally, the administration of olanzapine, similar to LiCl, increased phospho-Ser9-
GSK3β in brain (Li et al., 2007) (Figure 4). The inhibition of GSK3β by olanzapine was 
accompanied by a decrease in the blood glucose level and accumulation of glycogen in the 
liver in a dose-dependent manner. This is consistent with the effect of GSK3β inhibition 
(Mohammad et al., 2008). Olanzapine-induced low blood glucose level is also consistent 
with clinical reports (Budman & Gayer, 2001). This result contrasts that of a previous report, 
where olanzapine induced hyperglycemia as a major side effect (Fertig et al., 1998). The 
molecular mechanism of these contradictory findings is currently unknown. 
On the basis of the reported reduced cancer risk in schizophrenic patients (Catts et al., 2008), 
a recent study demonstrated the anti-tumor effect of a number of antipsychotic drugs, 
including olanzapine, except for risperidone (Wiklund et al., 2010). The effect of these drugs 
against cancer cells was associated with changes in the expression of genes acting on 
cholesterol homeostasis and the biophysical properties of the cellular membrane. Inhibition 
of GSK3β activity might be an alternate mechanism by which olanzapine acts against cancer. 
5.1.4 Cimetidine 
Cimetidine was the first registered histamine H2 receptor antagonist, and its frequent 
prescription was based on its clinical effectiveness in healing gastrointestinal ulcers by 
inhibiting gastric acid secretion (Somogyi & Gugler, 1983). Cimetidine has been 
demonstrated to possess anti-tumor activity against colon, gastric, and kidney cancers and 
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melanomas. This activity involves a number of different mechanisms of action, including 
blocking the cell growth-promoting activity of histamine (Lefranc et al., 2006). With respect 
to GBM, cimetidine combined with temozolomide was superior to temozolomide alone in 
extending the survival of nude mice with human GBM cells orthotopically xenografted into 
their brain (Lefranc et al., 2005).  
In silico screening is a powerful method to analyze large chemical databases in order to 
identify possible new drug candidates. Recently, in silico screening revealed that cimetidine, 
as well as hydroxychlorquine (an antimalarial and anti-lupus erythematosus agent) and 
gemifloxacin (a new quinolone antibiotic), have an inhibitory effect on GSK3β (Taha et al., 
2008) (Figure 4).  
5.1.5 Enzastaurin 
Enzastaurin, a selective serine/threonine protein kinase inhibitor already under clinical 
evaluation to treat recurrent GBM, potently inhibits GSK3β in addition to its primary target, 
protein kinase C (PKC) β. In phase I/II clinical trials, enzastaurin showed potentially 
encouraging efficacy in a subset of patients with recurrent malignant glioma, but does not 
appear to have enough single-agent activity to be useful as a monotherapy (Kreisl et al., 
2009; Kreisl et al., 2010). In this trial, phosphorylation of GSK3β in peripheral blood 
mononuclear cells was identified as a potential biomarker of drug activity. 
6. Perspective 
GSK3ǃ has been recognized as a key component in a wide range of cellular functions and is 
involved in the vast number of signaling pathways that converge on this enzyme, and 
subsequently, an even greater number of biological targets. GSK3β is undoubtedly a 
promising target not only for diabetes, bipolar disorder, Alzheimer’s, and several other 
neurological disorders, but also for human cancers, including GBM, on the basis of the 
accumulated evidence. Inhibitors of GSK3ǃ have enormous therapeutic potential. Of great 
importance is understanding the precise molecular mechanisms of GSK3β-mediated signal 
transduction, including signaling elements involved in proliferation, apoptosis, invasion, 
differentiation, chemosensitivity, radiosensitivity, and neuroprotection, as well as the 
precise functions of GSK3β proteins in cellular responses induced in human normal and 
malignant cell types. The emerging understanding of GSK3ǃ function would also give rise 
to new insights in tumor biology. In the future, it is hoped that increasing knowledge of 
GSK3β will be translated into molecularly targeted therapies against intractable cancers 
represented by glioblastoma multiforme. 
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